Evercore ISI Begins Coverage on Repligen (NASDAQ:RGEN)

Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN) in a report released on Tuesday, Marketbeat Ratings reports. The firm set an “in-line” rating and a $155.00 price target on the biotechnology company’s stock. Evercore ISI’s price objective points to a potential upside of 6.99% from the company’s previous close.

Several other equities analysts have also recently weighed in on RGEN. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group increased their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen presently has an average rating of “Hold” and a consensus price target of $178.64.

Repligen Price Performance

RGEN stock opened at $144.88 on Tuesday. The stock has a market capitalization of $8.12 billion, a PE ratio of -284.08, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company’s 50-day moving average is $156.78 and its 200-day moving average is $148.46. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 1 year low of $113.50 and a 1 year high of $200.23.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Equities research analysts expect that Repligen will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after acquiring an additional 743,815 shares during the period. Vanguard Group Inc. increased its position in shares of Repligen by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock valued at $734,251,000 after acquiring an additional 56,723 shares during the period. Champlain Investment Partners LLC increased its position in shares of Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock valued at $222,176,000 after acquiring an additional 122,595 shares during the period. Alliancebernstein L.P. increased its position in shares of Repligen by 23.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock valued at $145,508,000 after acquiring an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC increased its position in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after acquiring an additional 6,872 shares during the period. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.